

For Immediate Release

TSX Symbol: RVX

**Resverlogix moves closer to IND with the addition of Dr. Gregory S. Wagner
as Vice President Preclinical Development**

CALGARY, AB, April 25, 2006 – As preparation for entering into the clinical stage of its lead NexVas™ ApoA-I technology program Resverlogix Corp. (“Resverlogix”) (TSX: RVX) announced today that Dr. Gregory S. Wagner has joined the company as Vice President of Preclinical Development. Dr. Wagner will help lead the company’s efforts in developing its cardiovascular programs NexVas™ and ReVas™ towards IND (Investigational New Drug) submission to FDA (Food and Drug administration).

Dr. Wagner brings three decades of successful experience in early drug development to Resverlogix. He has worked with leading biotechnology and pharmaceutical companies such as Rigel Inc., Kosan Biosciences, and SUGEN (a subsidiary of Pharmacia eventually acquired by Pfizer Inc.). He has been responsible for managing the IND-enabling programs at these companies, including the pharmacology, toxicology, drug metabolism and pharmacokinetic studies. Dr. Wagner has played a leadership role in several important drug development projects, such as the SUGEN angiogenesis inhibitor program which cumulated in the successful development of the cancer drug SU11248- recently introduced by Pfizer under the brand name Sutent®.

“We are very pleased to add an individual well-experienced in preclinical drug development such as Dr. Wagner to our Scientific and Senior Management Team” stated Donald McCaffrey, President and CEO of Resverlogix. “Greg’s knowledge, successful track record and experience of FDA regulatory processes will greatly help our efforts in moving our leading CVD programs NexVas™ and ReVas™ forward to the next important step of development IND studies,” added Mr. McCaffrey. “It is very gratifying to once again attract an extremely qualified individual that had the choice of working with any number of key biotechnology companies, yet based on the development stage of our science and our business model has chosen to engage his services at Resverlogix”.

About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NexVas™, applies advanced medical research to develop therapies that increase ApoA-I the key protein of high density lipoprotein (HDL), the "good cholesterol," and other targets to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Donald J. McCaffrey

President/CEO

Resverlogix Corp.

Phone: 403-254-9252 ext. 223

Fax: 403-256-8495

Email: don@resverlogix.com

Kenneth Lebioda

Vice President Business Development

Resverlogix Corp.

Phone: 403-254-9252 ext. 227

Fax: 403-256-8495

Email: ken@resverlogix.com